| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MAY 2016. Refer to TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | canagliflozin (Invokana®) | |
| Formulation | 100 mg and 300 mg film-coated tablet | |
| Reference number | 2747 | |
| Indication | In adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 15/07/2015 | |
| Date of issue | 16/07/2015 | |
| NICE guidance | TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
|